Genetics of Neurodegenerative Dementias
Neurodegenerative dementias are among the most genetically complex disorders in neurology. Advances in genomic technologies — from linkage studies identifying monogenic forms to genome-wide association studies (GWAS) implicating dozens of susceptibility loci — have transformed our understanding of disease mechanisms. These discoveries carry direct clinical relevance: APOE genotyping now informs risk stratification before anti-amyloid immunotherapy, and genetic testing can establish a molecular diagnosis in familial cases, guiding counseling and clinical trial eligibility. This topic reviews the genetic architecture of the major neurodegenerative dementias, integrating insights from Mendelian genetics, GWAS, and the emerging AT(N) biomarker framework.
Bottom Line
- AD heritability: Estimated at ~70% in twin studies; a positive family history is the strongest biological risk factor after aging
- Familial AD: Autosomal dominant mutations in APP, PSEN1, and PSEN2 cause early-onset AD (~5% of cases) through increased Aβ production or decreased solubility
- APOEε4: The strongest common genetic risk factor for sporadic AD — heterozygous carriers have ~3× risk; homozygous carriers have ~15× risk; also increases risk of amyloid-related imaging abnormalities (ARIA) with anti-amyloid therapies
- AD GWAS: ~90 common variants across 75 loci identified, implicating innate immunity, lipid metabolism, and endocytosis pathways
- LBD genetics: GBA mutations are the most important genetic risk factor; GWAS has identified 5 reproducible loci (GBA, BIN1, TMEM175, SNCA, APOE) overlapping with both AD and Parkinson disease
- FTD genetics: ~40% have a family history; C9orf72 hexanucleotide repeat expansion is the most common cause of familial FTD (25%) and also causes 6% of sporadic cases
- Clinical implications: APOEε4 testing is now recommended before anti-amyloid therapy; genetic testing for familial dementia genes should be preceded by genetic counseling
Heritability and Familial Risk in Alzheimer Disease
The genetic contribution to AD risk is substantial. Twin studies estimate heritability at approximately 70%, and epidemiologic data consistently demonstrate that a positive family history is the strongest biological risk factor after aging. Having a single first-degree relative with AD increases risk by approximately 70%; two first-degree relatives raise the risk 4-fold, and four first-degree relatives increase risk nearly 15-fold compared with the general population. Even second- and third-degree relatives contribute to elevated risk, with greater numbers of affected relatives conferring higher risk.
Although approximately 95% of AD cases are sporadic with complex polygenic inheritance, roughly 5% follow autosomal dominant Mendelian patterns. Understanding both monogenic and polygenic contributions has been essential for elucidating disease pathways and developing targeted therapies.
Familial Alzheimer Disease: Monogenic Causes
APP, PSEN1, and PSEN2
Variants in three genes account for the vast majority of autosomal dominant early-onset AD:
| Gene | Chromosome | Protein | Variation Types | Mechanism |
|---|---|---|---|---|
| PSEN1 | 14 | Presenilin 1 | Missense | Most common cause of familial AD; alters γ-secretase activity, increasing Aβ42/Aβ40 ratio |
| PSEN2 | 1 | Presenilin 2 | Missense | Less common; similar mechanism to PSEN1 with altered γ-secretase function |
| APP | 21 | Amyloid precursor protein | Missense, duplication, deletions | Increased Aβ production or altered processing; duplications increase APP dosage |
The pathobiological consequence shared by all three genes is increased production or decreased solubility of Aβ, resulting in amyloid plaque formation. This finding — combined with evidence from transgenic mouse models showing that Aβ deposition also promotes tangle formation — forms the foundation of the amyloid cascade hypothesis, which posits that abnormal extracellular Aβ deposition initiates a sequence of downstream events including synaptic loss, plaque and tangle formation, and neuronal death.
The Amyloid Cascade Hypothesis in Practice
- The amyloid cascade hypothesis has driven treatment development for over 3 decades
- Three anti-amyloid immunotherapies have received FDA approval: aducanumab (2021, accelerated), lecanemab-irmb (2023), and donanemab-azbt (2024)
- These represent the first disease-modifying therapies for AD
- Familial AD mutations provided critical early evidence supporting the amyloid hypothesis and served as models for understanding sporadic disease
- A comprehensive database of variants in APP, PSEN1, and PSEN2 is maintained at alzforum.org/mutations
Sporadic Alzheimer Disease: APOE and GWAS Loci
APOE: The Major Susceptibility Gene
The apolipoprotein E gene (APOE) harbors the strongest and most common genetic risk factor for sporadic AD. The three major alleles — ε2, ε3, and ε4 — differ by single amino acid substitutions and have markedly different effects on AD risk:
| APOE Allele | Population Frequency | Effect on AD Risk | Key Features |
|---|---|---|---|
| ε2 | ~5–10% | Protective | Associated with reduced AD risk and later age of onset; may have neuroprotective properties |
| ε3 | ~60–70% | Neutral (reference) | Most common allele; represents baseline population risk |
| ε4 | 15–25% general population; ~50% of AD patients | Increased risk | Heterozygous: ~3× risk; Homozygous: ~15× risk; earlier age of onset; dose-dependent effect |
APOEε4 has multiple functions that are not completely understood. One key pathogenic mechanism involves impaired Aβ transport and clearance across the blood-brain barrier, resulting in amyloid plaque formation. The same mechanism drives cerebral amyloid angiopathy (CAA), a frequent copathology in AD, whereby APOEε4 promotes Aβ deposition in the tunica media of small and medium-sized arteries, leading to smooth muscle cell death and susceptibility to intracerebral hemorrhage.
APOEε4 and Anti-Amyloid Therapy Risk
- APOEε4 carriers are at high risk for amyloid-related imaging abnormalities (ARIA) on brain MRI, related to underlying cerebral amyloid angiopathy
- ARIA includes vasogenic edema (ARIA-E) and intracerebral hemorrhage (ARIA-H) — well-recognized adverse events of anti-amyloid therapies
- Risk is dose-dependent: homozygous ε4/ε4 carriers face higher ARIA risk than heterozygotes
- APOE genotyping is now recommended before initiating anti-amyloid therapy (lecanemab, donanemab) for risk stratification
- Results inform frequency of safety monitoring, dosing adjustments, and the risk-benefit discussion with patients
- Pretreatment genetic counseling is essential
Importantly, ethnic and racial background modulates the APOEε4 association with AD: people of African or Hispanic ancestry carrying APOEε4 have a lower risk compared with White populations. This highlights the importance of studying diverse populations and exercising caution in applying risk estimates derived from primarily European-ancestry cohorts.
GWAS-Identified Risk Loci
GWAS approaches have identified approximately 90 common variants across 75 loci contributing to AD susceptibility. Although each individual locus confers modest risk, their combined effect — estimated using polygenic risk scores — explains approximately 11% of the genetic liability to AD. The remaining “missing heritability” may be attributed to rare variants, gene–environment interactions, structural variants, or variants in complex genomic regions not well captured by current methods.
| Gene/Locus | Protein/Function | Implicated Pathway | Key Notes |
|---|---|---|---|
| TREM2 | Triggering receptor expressed on myeloid cells 2 | Innate immunity / microglial function | Rare variants confer high risk (OR 2–4); key role in microglial response to amyloid |
| ABCA7 | ATP-binding cassette transporter A7 | Lipid metabolism / phagocytosis | Stronger risk in individuals of African ancestry |
| BIN1 | Bridging integrator 1 | Endocytosis / tau pathology | Also a reproducible risk locus for Lewy body dementia |
| CLU | Clusterin (Apolipoprotein J) | Lipid metabolism / Aβ clearance | Involved in Aβ aggregation and transport |
| CR1 | Complement receptor 1 | Innate immunity / complement cascade | Supports role of neuroinflammation in AD |
| PICALM | Phosphatidylinositol-binding clathrin assembly protein | Endocytosis / Aβ clearance | Mediates endocytic trafficking at the blood-brain barrier |
Pathway Insights from GWAS
Pathway enrichment analyses from GWAS data have implicated three major biological systems in AD pathogenesis:
- Innate immune system: Genes like TREM2, CR1, and the HLA locus implicate microglial activation and neuroinflammation; anti-inflammatory strategies are being explored as therapeutic avenues
- Lipid metabolism: Genes including APOE, ABCA7, and CLU highlight the role of cholesterol transport and lipid processing in Aβ clearance and aggregation
- Endocytosis: BIN1, PICALM, and related loci point to endolysosomal dysfunction as a key contributor to both amyloid and tau pathology
These findings suggest that future therapies may need to adopt multitarget approaches tailored to individual patient risk profiles and disease stage, extending beyond amyloid-focused strategies alone.
Lewy Body Dementia Genetics
Lewy body dementia (LBD) is the second most common neurodegenerative dementia after AD, affecting approximately 1.4 million people in the United States. It is an etiologically complex disorder usually manifesting as a sporadic condition of late adulthood. However, rare familial occurrences suggest that genetic risk factors play a significant role. The genetic architecture of LBD partially overlaps with both AD and Parkinson disease, reflecting shared biological pathways.
Major Genetic Risk Factors
| Gene | Protein | Variation Type | Inheritance | Key Details |
|---|---|---|---|---|
| GBA | β-glucocerebrosidase | Missense, loss-of-function | Reduced penetrance / high-risk allele | Found in 13% of LBD patients; 30% in Ashkenazi Jewish LBD patients; variants classified as mild or severe (per Gaucher disease scheme) |
| SNCA | α-synuclein | Missense, duplication, triplication | Autosomal dominant (rare) | Rare familial cause; common variants at SNCA also confer sporadic risk; association signal differs from Parkinson disease |
| APOE | Apolipoprotein E | Common polymorphism | Risk allele | ε4 allele is a shared risk factor for both AD and LBD |
| LRRK2 | Leucine-rich repeat kinase 2 | Missense | Autosomal dominant (incomplete penetrance) | Major Parkinson disease gene; some carriers develop dementia consistent with LBD spectrum |
GBA variants are the single most important genetic risk factor for LBD. In Parkinson disease, severe GBA variant carriers manifest disease approximately 5 years earlier than mild variant carriers (53 versus 58 years). These variants implicate lysosomal dysfunction as a central mechanism in synucleinopathies.
GWAS Findings in Lewy Body Dementia
GWAS studies have reproducibly identified five risk loci for LBD:
| Locus | Also a Risk Locus For | Implicated Pathway |
|---|---|---|
| GBA | Parkinson disease, Gaucher disease | Lysosomal function |
| BIN1 | Alzheimer disease | Endocytosis |
| TMEM175 | Parkinson disease | Endolysosomal function |
| SNCA | Parkinson disease | α-synuclein biology |
| APOE | Alzheimer disease | Lipid metabolism / Aβ clearance |
These findings illustrate the partially overlapping genetic architectures among AD, Parkinson disease, and LBD. Pathway enrichment analysis has implicated shared pathways including endolysosomal function, regulation of endocytosis, Aβ formation, and tau-protein binding — highlighting potential cross-disease therapeutic targets.
Genetic Pleiotropy in Neurodegenerative Dementias
- Multiple genes are shared across dementia syndromes: APOEε4 and BIN1 are risk factors for both AD and LBD
- GRN (progranulin) variants have been associated with AD, Parkinson disease, LBD, and FTD
- Carriers of familial AD mutations (APP, PSEN1, PSEN2) commonly demonstrate Lewy body copathology at autopsy
- These overlapping genetic architectures suggest shared biological pathways — particularly endolysosomal dysfunction and neuroinflammation — that may be targeted for therapy development across diseases
Frontotemporal Dementia Genetics
Frontotemporal dementia (FTD) is the second most common early-onset dementia after AD. Genetic factors play a particularly prominent role: approximately 40% of patients report a family history. The underlying neuropathology — frontotemporal lobar degeneration (FTLD) — is classified by the predominant proteinopathy: FTLD-tau, FTLD-TDP, FTLD-FUS, or FTLD-UPS.
Major FTD Genes
| Gene | Chromosome | Protein | Variation Type | FTLD Subtype | Key Features |
|---|---|---|---|---|---|
| C9orf72 | 9 | C9orf72 | [GGGGCC]n hexanucleotide repeat expansion | FTLD-TDP | Most common genetic cause of familial FTD (25%) and ALS; 6% of sporadic FTD; autosomal dominant |
| GRN | 17 | Progranulin | Missense, splice site, deletion, loss-of-function | FTLD-TDP | Haploinsufficiency mechanism; associated with TDP-43 type A pathology; pleiotropic effects across multiple dementias |
| MAPT | 17 | Microtubule-associated protein tau | Missense, splice site | FTLD-tau | Causes FTD with parkinsonism linked to chromosome 17; 3R, 4R, or mixed tau pathology |
Rare FTD Genes
An increasing number of less common familial FTLD genes have been identified, providing insights into disease-associated pathways:
| Gene | Implicated Pathway |
|---|---|
| VCP | Protein homeostasis / ubiquitin-proteasome system |
| CHMP2B | Endosomal sorting / autophagy |
| FUS | RNA transcription / processing |
| TBK1 | Innate immunity / autophagy |
| TARDBP | RNA metabolism (encodes TDP-43) |
| SQSTM1 | Autophagy (encodes p62) |
| OPTN, UBQLN2 | Protein clearance pathways |
| CCNF, KIF5A, TUBA4A, DCTN1 | Cytoskeletal transport |
| CHCHD10 | Mitochondrial function |
These rare variants collectively implicate impairments in RNA transcription, protein homeostasis, cytoskeletal transport, and mitochondrial function as key pathogenic mechanisms in FTLD. The increasing availability of gene panel testing and whole-exome sequencing has expanded opportunities to screen for these variants and establish molecular diagnoses.
GWAS in Frontotemporal Dementia
Sporadic cases of FTLD account for approximately 60% of cases. Key GWAS findings include:
- MAPT locus: Associated with the tauopathies PSP and CBD
- TMEM106B: Associated with FTLD-TDP; highlights lysosomal dysfunction
- HLA locus: Supports a role of the immune system in FTLD pathogenesis
- DPP6 and UNC13A: Significantly associated with FTLD-TDP
- RAB38 and CTSC: Suggested association with behavioral variant FTD; implicate lysosomal biology
Huntington Disease Genetics
Huntington disease (HD) is an autosomal dominant disorder caused by expansion of CAG (polyglutamine) trinucleotide repeats within the HTT gene on chromosome 4, which encodes huntingtin — a ubiquitous scaffolding protein with roles in intracellular transport, autophagy, and transcription.
| CAG Repeat Range | Clinical Significance |
|---|---|
| ≤26 repeats | Normal; no HD risk |
| 27–35 repeats | Intermediate (mutable normal); no clinical disease but may expand in offspring |
| 36–39 repeats | Reduced penetrance; may or may not develop HD |
| ≥40 repeats | Full penetrance; HD will develop if the individual lives long enough |
The size of the CAG expansion correlates inversely with the age of onset and influences clinical manifestations. Juvenile-onset HD (typically ≥60 repeats) tends to present with rigidity and seizures rather than the classic choreiform movements. Neuropathologically, HD is characterized by prominent atrophy of the caudate and putamen with loss of medium spiny neurons, graded using the Vonsattel system (grades 0–4). Abnormal ubiquitinated huntingtin aggregates form neuronal inclusions in the striatum, neocortex, entorhinal cortex, and hippocampus.
Prion Disease Genetics
Genetic prion diseases are caused by mutations in the PRNP gene, which encodes the prion protein (PrP). Although less common than sporadic Creutzfeldt-Jakob disease, familial forms include:
- Familial Creutzfeldt-Jakob disease: Rapidly progressive dementia with extrapyramidal/pyramidal signs, ataxia, and myoclonus; predominantly involves the neocortex
- Gerstmann-Sträussler-Scheinker syndrome: Cerebellar ataxia with progressive dementia; characterized by multicentric PrP amyloid plaques in the cerebellar cortex
- Fatal familial insomnia: Progressive insomnia and dysautonomia; predominantly affects the thalamus
Specific PRNP pathogenic variants are associated with particular neuropathologic phenotypes. The abnormal PrP protein is unique for its self-propagating and transmissible nature. A common polymorphism at codon 129 of PRNP (methionine/valine) modulates susceptibility to both genetic and sporadic prion diseases.
CADASIL: NOTCH3 Mutations
Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is the most common hereditary cause of vascular dementia and recurrent stroke, caused by mutations in NOTCH3 on chromosome 19. The majority of pathogenic variants are cysteine-altering changes that lead to misfolding and aggregation of the Notch3 extracellular domain.
CADASIL: Clinical and Pathologic Features
- Typical presentation: recurrent subcortical ischemic strokes, progressive cognitive decline, migraine with aura, and mood disturbances
- MRI signature: confluent white matter hyperintensities with characteristic involvement of the anterior temporal poles and external capsules
- Pathology: granular osmiophilic material (GOM) within the media of small arteries, with thickened vessel walls, smooth muscle cell replacement, and resultant lacunar and cystic infarcts predominantly in white matter
- Genetic testing: sequencing of NOTCH3 exons 2–24; skin biopsy for GOM deposits can support diagnosis
- Over 250 pathogenic NOTCH3 variants have been reported, most commonly in exons 3–6
Genetic Testing in Clinical Practice
Genetic testing for familial forms of dementia has become more widely accessible in recent years. The decision to pursue testing requires careful consideration of indications, limitations, and the need for genetic counseling.
When to Consider Genetic Testing
| Scenario | Testing Approach | Considerations |
|---|---|---|
| Early-onset AD (<65 years) with family history | Gene panel (APP, PSEN1, PSEN2) | Autosomal dominant pattern; genetic counseling essential before and after testing |
| FTD with family history | C9orf72 repeat expansion, GRN, MAPT; expanded panels if negative | ~40% of FTD patients have family history; molecular diagnosis enables refined counseling and trial eligibility |
| Suspected Huntington disease | HTT CAG repeat analysis | Confirmatory test; predictive testing in at-risk individuals requires extensive pre-test counseling |
| Suspected prion disease with family history | PRNP sequencing | Distinguishes genetic from sporadic forms; implications for family members |
| Suspected CADASIL | NOTCH3 sequencing | Confirm in patients with characteristic MRI pattern and/or family history of stroke/dementia |
| Mild cognitive impairment/mild AD considering anti-amyloid therapy | APOE genotyping | Risk stratification for ARIA; informs monitoring frequency and dosing; genetic counseling required |
Important Principles of Genetic Testing in Dementia
- Genetic testing should only be performed after appropriate counseling about advantages and disadvantages
- Routine testing for high-risk alleles (e.g., APOE) is not recommended in the general population and is currently limited to research studies
- The notable exception is APOEε4 testing in patients with MCI or mild AD who are considering anti-amyloid immunotherapy
- Predictive testing in asymptomatic at-risk individuals (e.g., HD) requires specialized genetic counseling protocols
- Gene panel testing and whole-exome sequencing have expanded the ability to identify rare variants, but interpretation of variants of uncertain significance remains challenging
- A positive genetic diagnosis can facilitate participation in targeted clinical trials and natural history studies
Biomarkers and the AT(N) Framework
As disease-modifying therapies enter clinical practice, the use of biomarkers to diagnose and stage AD in living patients has become critically important. The revised 2024 NIA-AA diagnostic criteria incorporate the AT(N) classification and expand it to include additional pathologic processes:
| Category | Pathogenic Process | CSF Biomarkers | Plasma Biomarkers | Imaging |
|---|---|---|---|---|
| A | Aβ proteinopathy | Aβ42, Aβ42/Aβ40 ratio | Aβ42 | Amyloid PET |
| T | Tau proteinopathy | pTau181, pTau205, pTau231, MTBR-Tau243 | pTau217 | Tau PET |
| (N) | Neurodegeneration | Neurofilament light chain (NfL) | NfL | Structural MRI, FDG-PET |
| I | Inflammation | GFAP | GFAP | — |
| S | α-synuclein proteinopathy | α-synuclein seeding amplification assay | — | — |
| V | Vascular injury | — | — | MRI (infarcts, WMH, enlarged perivascular spaces) |
This framework bridges genetics and clinical practice: patients identified as carrying high-risk genetic variants (e.g., APOEε4 homozygotes) can be monitored with biomarkers for early evidence of amyloid and tau pathology. Over 10% of individuals with preclinical AD also harbor α-synuclein pathology, underscoring the importance of comprehensive biomarker profiling. As therapeutic options expand, integrating genetic risk assessment with the AT(N) biomarker framework will be essential for precision medicine approaches to dementia care.
Summary of Genetic Architecture Across Neurodegenerative Dementias
| Disease | Monogenic Genes | Major Risk Alleles | Estimated Heritability | GWAS Loci |
|---|---|---|---|---|
| Alzheimer disease | APP, PSEN1, PSEN2 | APOEε4, TREM2, ABCA7 | ~70% | ~90 variants / 75 loci |
| Lewy body dementia | SNCA, GBA | GBA, APOEε4, SNCA | Under investigation | 5 reproducible loci |
| FTD / FTLD | C9orf72, GRN, MAPT | TMEM106B, MAPT H1 haplotype | ~40% familial | Multiple loci identified |
| Huntington disease | HTT (CAG expansion) | — | 100% (fully penetrant ≥40 repeats) | — |
| Prion diseases | PRNP | Codon 129 polymorphism | Variable by subtype | — |
| CADASIL | NOTCH3 | — | 100% (autosomal dominant) | — |
References
- Scholz SW, Cobos I. Genetics and neuropathology of neurodegenerative dementias. Continuum (Minneap Minn). 2024;30(6, Dementia):1801-1822.
- Cannon-Albright LA, Foster NL, Schliep K, et al. Relative risk for Alzheimer disease based on complete family history. Neurology. 2019;92(15):e1745-e1753.
- Karlsson IK, Escott-Price V, Gatz M, et al. Measuring heritable contributions to Alzheimer’s disease: polygenic risk score analysis with twins. Brain Commun. 2022;4(1):fcab308.
- Bellenguez C, Kucukali F, Jansen IE, et al. New insights into the genetic etiology of Alzheimer’s disease and related dementias. Nat Genet. 2022;54(4):412-436.
- Wightman DP, Jansen IE, Savage JE, et al. A genome-wide association study with 1,126,563 individuals identifies new risk loci for Alzheimer’s disease. Nat Genet. 2021;53(9):1276-1282.
- Hardy JA, Higgins GA. Alzheimer’s disease: the amyloid cascade hypothesis. Science. 1992;256(5054):184-185.
- Filippi M, Cecchetti G, Spinelli EG, et al. Amyloid-related imaging abnormalities and beta-amyloid-targeting antibodies: a systematic review. JAMA Neurol. 2022;79(3):291-304.
- Chia R, Sabir MS, Bandres-Ciga S, et al. Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture. Nat Genet. 2021;53(3):294-303.
- Sidransky E, Nalls MA, Aasly JO, et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson’s disease. N Engl J Med. 2009;361(17):1651-1661.
- Nalls MA, Duran R, Lopez G, et al. A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies. JAMA Neurol. 2013;70(6):727-735.
- Majounie E, Renton AE, Mok K, et al. Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurol. 2012;11(4):323-330.
- Grossman M, Seeley WW, Boxer AL, et al. Frontotemporal lobar degeneration. Nat Rev Dis Primers. 2023;9(1):40.
- Jack CR, Andrews JS, Beach TG, et al. Revised criteria for diagnosis and staging of Alzheimer’s disease: Alzheimer’s Association Workgroup. Alzheimers Dement. 2024;20(8):5143-5169.
- Stepler KE, Gillyard TR, Reed CB, et al. ABCA7, a genetic risk factor associated with Alzheimer’s disease risk in African Americans. J Alzheimers Dis. 2022;86(1):5-19.
- Andrews SJ, Renton AE, Fulton-Howard B, et al. The complex genetic architecture of Alzheimer’s disease: novel insights and future directions. EBioMedicine. 2023;90:104511.